Peter Houghton J. PhD

Peter Houghton J. PhD
ProfessorCollege of MedicinePeter.Houghton@nationwidechildrens.org
Children's Hospital 700 Children's Drive Columbus OH 43205
Phone:(614) 355-2670Fax:
  • Administrative
  • Translational Therapeutics

Research Description

The Houghton Lab is focused on understanding the basic biology of childhood solid tumors, largely sarcoma. Dr. Houghton has identified a chromosomal rearrangement in rhabdomyosarcoma that leads to downstream over-expression of insulin-like growth factor 2 (IGF2) ligand. His lab is working to interpret the signaling pathway and is developing therapeutic approaches to block IGF signaling in rhabdomyosarcoma, Wilms’ tumors, neuroblastoma, Ewing sarcomas, and a range of other tumors.

Current Publications

  • Gorlick R, Billups CA, Hawthorne T, Kurmasheva RT, Houghton PJ, Smith MA, Kolb EAInitial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.Pediatr Blood Cancer 61 1816-21 10/1/2014
  • Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Wu J, Smith MA, Houghton PJ, Kurmasheva RT, Lyalin DInitial solid tumor testing (Stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.Pediatr Blood Cancer in press 8/17/2014
  • Paoloni M, Kaplan R, Teicher BA, Seibel NL, Smith M, Uren A, Patel SR, Trent J, Savage SA, Mirabello L, Reinke D, Barkaukas DA, Krailo M, Bernstein M, Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ES, Adamson PC, Houghton PJ, Tap WD, Welch DR, Steeg PS, Merlino G, Sorensen PH, Meltzer P, Kirsch DG, Janeway KA, Weigel B, Randall L, Withrow SJToward a drug development path that targets metastatic progression in osteosarcoma.Clin Cancer Res 20 4200-9 8/15/2014
  • Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Wu J, Kurmasheva RT, Houghton PJ, Smith MA, Lock RBInitial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.Pediatr Blood Cancer 61 1493-6 8/1/2014
  • Kang MH, Reynolds CP, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MAInitial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program.Pediatr Blood Cancer 61 1486-9 8/1/2014
  • Suryani S, Carol H, Chonghaile TN, Frismantas V, Sarmah C, High L, Bornhauser B, Cowley MJ, Szymanska B, Evans K, Boehm I, Tonna E, Jones L, Manesh DM, Kurmasheva RT, Billups C, Kaplan W, Letai A, Bourquin JP, Houghton PJ, Smith MA, Lock RBCell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts.Clin Cancer Res in press 7/10/2014
  • Kishore N, Binneman B, Mahapatra A, van de Venter M, du Plessis-Stoman D, Boukes G, Houghton P, Marion Meyer JJ, Lall NCytotoxicity of synthesized 1,4-naphthoquinone analogues on selected human cancer cell lines.Bioorg Med Chem in press 7/4/2014
  • Ingle AM, Ahern CH, Ames MM, Houghton P, Doyle LA, Weigel B, Blaney SM, Fouladi M, Perentesis JP, Phillips CL, Leary S, Reid JM, McGovern RMA phase I trial of MK-2206 in children with refractory malignancies: a Children's Oncology Group study.Pediatr Blood Cancer 61 1246-51 7/1/2014
  • Kurmasheva RT, Reynolds CP, Kang MH, Allievi C, Houghton PJ, Smith MAInitial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.Pediatr Blood Cancer 61 922-4 5/1/2014
  • Fleuren ED, Versleijen-Jonkers YM, Roeffen MH, Franssen GM, Flucke UE, Houghton PJ, Oyen WJ, Boerman OC, van der Graaf WTTemsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.Int J Cancer in press 4/26/2014
  • Rath KS, Naidu SK, Lata P, Bid HK, Rivera BK, McCann GA, Tierney BJ, Elnaggar AC, Bravo V, Leone G, Houghton P, Hideg K, Kuppusamy P, Cohn DE, Selvendiran KHO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer.Cancer Res 74 2316-27 4/15/2014
  • Cam M, Bid HK, Xiao L, Zambetti GP, Houghton PJ, Cam Hp53/TAp63 and AKT regulate mammalian target of rapamycin complex 1 (mTORC1) signaling through two independent parallel pathways in the presence of DNA damage.J Biol Chem 289 4083-94 2/14/2014
  • Houghton PJ, Kurmasheva RT, Kolb EA, Wu J, Gorlick R, Maris JM, Smith MAInitial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 61 380-2 2/1/2014
  • Carol H, Gorlick R, Kolb EA, Morton CL, Manesh DM, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak A, Hickson I, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA, Lock RInitial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 61 245-52 2/1/2014
  • Hutzen B, Bid HK, Houghton PJ, Pierson CR, Powell K, Bratasz A, Raffel C, Studebaker AWTreatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin.BMC Cancer 14 206 1/1/2014
  • Bid HK, Roberts RD, Cam M, Audino A, Kurmasheva RT, Lin J, Houghton PJ, Cam HΔNp63 promotes pediatric neuroblastoma and osteosarcoma by regulating tumor angiogenesis.Cancer Res 74 320-9 1/1/2014
  • Gorlick R, Kolb EA, Keir ST, Maris JM, Reynolds CP, Kang MH, Carol H, Lock R, Billups CA, Kurmasheva RT, Houghton PJ, Smith MAInitial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 61 158-64 1/1/2014
  • Kurmasheva RT, Mo X, Fernandez S, Houghton PJ, Bid HK, Kibler A, Phelps DA, Manap S, Xiao L, Lin J, Capper D, Oswald D, Geier B, DeWire M, Smith PDDevelopment, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma.Clin Cancer Res 19 6716-29 12/15/2013
  • Hsu SH, Wang B, Kutay H, Bid H, Shreve J, Zhang X, Costinean S, Bratasz A, Houghton P, Ghoshal KHepatic loss of miR-122 predisposes mice to hepatobiliary cyst and hepatocellular carcinoma upon diethylnitrosamine exposure.Am J Pathol 183 1719-30 12/1/2013
  • Wood AC, Maris JM, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Wu J, Kurmasheva RT, Whiteman K, Houghton PJ, Smith MAInitial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.Pediatr Blood Cancer 60 1860-7 11/1/2013
  • Houghton PJNew insights into drug development for pediatric solid tumors: what preclinical data justify clinical trials in pediatric cancer?Expert Rev Anticancer Ther 13 1135-8 10/1/2013
  • Bid HK, Roberts RD, Manchanda PK, Houghton PJRAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis.Mol Cancer Ther 12 1925-34 10/1/2013
  • Billups CA, Desjardins C, Kurmasheva RT, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, Keir ST, Maris JM, Houghton PJ, Smith MAInitial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program.Pediatr Blood Cancer 60 1325-32 8/1/2013
  • Balkhi MY, Balkhi MY, Iwenofu OH, Kraybill W, Perrotti D, Croce CM, Keller C, Guttridge DC, Bakkar N, Ladner KJ, Chandler DS, Houghton PJ, London CAmiR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR.Sci Signal 6 ra63 7/30/2013
  • Shen C, Houghton PJThe mTOR pathway negatively controls ATM by up-regulating miRNAs.Proc Natl Acad Sci U S A 110 11869-74 7/16/2013
  • Lock RB, Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Billups CA, Kurmasheva RT, Houghton PJ, Smith MAInitial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 60 E42-5 7/1/2013
  • Smith MA, Houghton PA proposal regarding reporting of in vitro testing results.Clin Cancer Res 19 2828-33 6/1/2013
  • Houghton PJ, Shen C, Oswald D, Phelps D, Cam H, Pelloski CE, Pang QRegulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks.Cancer Res 73 3393-401 6/1/2013
  • Bid HK, London CA, Gao J, Zhong H, Hollingsworth RE, Fernandez S, Mo X, Houghton PJDual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy.Clin Cancer Res 19 2984-94 6/1/2013
  • Reynolds CP, Kang MH, Carol H, Lock R, Gorlick R, Kolb EA, Kurmasheva RT, Keir ST, Maris JM, Billups CA, Houghton PJ, Smith MAInitial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.Pediatr Blood Cancer 60 791-8 5/1/2013
  • Kang MH, Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MA, Keir ST, Maris JM, Reynolds CPInitial testing (stage 1) of temozolomide by the pediatric preclinical testing program.Pediatr Blood Cancer 60 783-90 5/1/2013
  • Smith MA, Lock RB, Carol H, Szymanska B, Evans K, Boehm I, Houghton PJThe anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.Clin Cancer Res 19 1795-805 4/1/2013
  • Reynolds CP, Kang MH, Keir ST, Maris JM, Gorlick R, Kolb EA, Billups CA, Geier B, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB, Carol HInitial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 60 633-41 4/1/2013
  • Kaplon R, Hadziahmetovic M, Sommerfeld J, Bondra K, Lu L, Leasure J, Nguyen P, McHugh K, Li N, Chronowski C, Sebastian N, Singh M, Kurmasheva R, Houghton P, Pelloski CEThe application of radiation therapy to the Pediatric Preclinical Testing Program (PPTP): results of a pilot study in rhabdomyosarcoma.Pediatr Blood Cancer 60 377-82 3/1/2013
  • Gorlick R, Kolb EA, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MAInitial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.Pediatr Blood Cancer 59 1266-74 12/15/2012
  • Batra V, Maris JM, Kang MH, Reynolds CP, Houghton PJ, Alexander D, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Billups CA, Smith MAInitial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.Pediatr Blood Cancer 59 749-52 10/1/2012
  • Smith MA, Kang MH, Reynolds CP, Kurmasheva RT, Alexander D, Billups CA, Toretsky JA, Houghton PJEvaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.Pediatr Blood Cancer 59 753-5 10/1/2012
  • Kurmasheva RT, Kolb EA, Keir ST, Reynolds CP, Kang MH, Billups CA, Smith MA, Gorlick R, Maris JM, Houghton PJ, Lock R, Carol HTesting of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 59 518-24 9/1/2012
  • Keir ST, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MAInitial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 59 586-8 9/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu